People with Parkinson's disease who have a pacemaker-like device implanted in the brain spend an extra four-plus hours a day free of tremors and involuntary movements than they do on medication, ...

We anticipate Livanova can bring leverage down to the target range by 2027, which would put the firm's debt at levels typical of medtech firms. Interest coverage remains well within covenants, though, ...

For the one million people diagnosed with Parkinson's disease in the United States, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug ...

Medtronic gets US FDA nod for the world’s first adaptive deep brain stimulation system for people with Parkinson’s disease: Galway, Ireland Saturday, March 1, 2025, 09:00 Hrs ...

The FDA approves BrainSense Adaptive deep brain stimulation and electrode identifier technology for the treatment of ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, the growing measles outbreak in Texas, ...

The FDA has approved Medtronic's Brainsense Adaptive deep brain stimulation for patients with Parkinson's disease. The technology is designed to adjust therapy in real time based on a patient's brain ...

The FDA has approved BrainSense, an adaptive deep brain stimulation system that can adjust therapy for Parkinson’s disease in ...

The biggest technical challenge for adaptive deep brain stimulation (aDBS) is how small brain signals are, Medtronic's Scott ...

The FDA has approved adaptive deep brain stimulation (aDBS), a breakthrough therapy that adjusts in real time to Parkinson’s disease symptoms.

Galifianakis, MD, while testing a deep brain stimulation treatment for Parkinson's disease ... The FDA approval covers two ...

After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive ...